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Abstract
Background
Following one to five years of antibiotic mass drug administration (MDA) for the elimination
of trachoma as a public health problem, programmes must conduct impact surveys to inform
decisions on whether MDA is still needed. These decisions are currently based on the prev-
alence of trachomatous inflammation—follicular (TF), which, after MDA, correlates poorly
with prevalence of ocular Chlamydia trachomatis infection.
Methodology/Principal findings
Impact surveys in six evaluation units (EUs) of Malawi were used as a platform to explore
associations between the prevalence of TF, ocular C. trachomatis infection and anti-Pgp3
antibodies one year after the third annual round of MDA. Participants were examined for tra-
choma using the World Health Organization simplified grading system. Ocular swabs and
dried blood spots (DBS) were collected from children aged 1–9 years. Swabs were tested
for C. trachomatis DNA using GeneXpert. DBS were assayed for anti-Pgp3 antibodies using
ELISA. EU-level prevalence of TF in children aged 1–9 years ranged from 4.7% (95% CI
3.4–6.3) to 7.2% (95% CI 5.8–8.9). Prevalence of C. trachomatis infection in children ranged
from 0.1% (95% CI 0.0–0.6) to 0.7% (95% CI 0.3–1.3) while Pgp3 seroprevalence ranged
from 6.9% (95% CI 5.4–8.6) to 12.0% (95% CI 10.1–14.0) and increased with age.
Conclusions/Significance
Based on current global policy, the prevalence of TF indicates that a further year of antibiotic
MDA is warranted in four of six EUs yet the very low levels of infection cast doubt on the uni-
versal applicability of TF-based cut-offs for antibiotic MDA. Pgp3 seroprevalence was similar
to that reported following MDA in other settings that have reached the elimination target
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however the predictive value of any particular level of seropositivity with respect to risk of
subsequent infection recrudescence is, as yet, unknown.
Author summary
Trachoma, caused by ocular infection with the bacterium Chlamydia trachomatis, is
treated at the population level with mass drug administration (MDA) of azithromycin, a
broad-spectrum antibiotic. Decisions to stop MDA are subsequently made following
impact surveys designed to determine the prevalence of trachoma in children aged 1–9
years. However, clinical signs of trachoma can persist in treated communities even in the
absence of active C. trachomatis infection, potentially leading to continued MDA that
may be unnecessary. In this study, we use the platform provided by six impact surveys to
compare prevalence of clinical signs of trachoma in children with prevalence of C. tracho-
matis infection and anti-C. trachomatis antibodies. Based on current policy, prevalence of
clinical signs of trachoma in four of six evaluation units surveyed indicated further MDA
is warranted. However, tests for C. trachomatis DNA indicate extremely low levels of
infection making the need for further MDA unclear. Prevalence of anti-C. trachomatis
antibodies were similar to that found in other low prevalence settings, however the signifi-
cance of such levels, and of levels of current C. trachomatis infection, with regard to the
risk of reinfection are, as yet, unknown.
Introduction
Trachoma, caused by repeated infection with the obligate intracellular bacterium Chlamydia
trachomatis, is a leading cause of preventable blindness. Elimination of trachoma as a public
health problem can be achieved through implementation of the multi-faceted SAFE strategy:
Surgery to correct trichiasis, Antibiotics to treat ocular C. trachomatis infection, and Facial
cleanliness and Environmental improvement to reduce transmission [1–2].
The A, or antibiotic, component of SAFE is carried out at the district level through mass
drug administration (MDA) of the macrolide antibiotic azithromycin. Prevalence of tracho-
matous inflammation—follicular (TF) in children aged 1–9 years currently guides MDA
decision-making. One to five years of district-level MDA is undertaken wherever baseline
prevalence of TF in children aged 1–9 years is�5%. The decision to stop MDA is again based
on the prevalence of TF, determined through adequately powered impact surveys [3]. If the TF
prevalence in children aged 1–9 years remains�5%, district-level MDA may continue.
The use of TF as the sole indicator to guide decisions on whether to continue or cease
MDA following impact surveys may be problematic because low levels of TF can persist in the
absence of ocular C. trachomatis infection [4]. Follicular conjunctivitis can be associated with
non-chlamydial bacterial infection [5–6] or be of uncertain aetiology, even in apparently tra-
choma-endemic populations [7]. Furthermore, as active trachoma prevalence declines, it
becomes increasingly difficult to train graders for surveys and to prove that graders have been
trained well [8]. These issues have led to suggestions that alternate indicators for use in MDA
decision-making and post-MDA surveillance be explored [9–10]. Possible alternatives include
nucleic acid amplification-based tests for ocular C. trachomatis infection and assays for the
presence of anti-C. trachomatis antibodies [11–12].
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Malawi represents an ideal setting in which to assess the utility of alternate indicators for
trachoma elimination programmes. Health officials have known Malawi to be endemic for tra-
choma since the 1980s [13] although an active control programme was not put in place until a
decade ago. The Trachoma Action Plan was developed and launched by the Ministry of Health
in 2011. The Global Trachoma Mapping Project completed mapping trachoma in Malawi in
2015 and showed, in combination with data collected previously, that 17 of 28 districts had TF
prevalence between 10 and 25% [14–16]. Funding to implement the SAFE strategy in these 17
districts was made possible through the Queen Elizabeth Diamond Jubilee Trust in 2014, with
the goal of eliminating trachoma by 2019. Several districts have since completed three rounds
of MDA with high treatment coverage [17] and have proceeded to impact surveys, following
WHO guidelines. To date, approximately half the population has received MDA and six thou-
sand individuals have received surgery for trichiasis. The aim of the present study was to gen-
erate, in a programmatic setting, additional data on C. trachomatis infection and anti-Pgp3
antibodies as possible alternative indicators for making decisions as to whether or not to stop
MDA.
Methods
Study site
The study was conducted in two districts: Chikwawa in southern Malawi (estimated popula-
tion 565,000) [18] and Mchinji (est. pop. 600,000) [18] in central Malawi. Trachoma preva-
lence was previously assessed in both districts through surveys conducted in 2008 [14]; the
prevalence of TF in children aged 1–9 years was 13.6% in Chikwawa and 21.7% in Mchinji.
Prevalence of trichiasis in adults aged�15 years was 0.6% (Chikwawa) and 0.3% (Mchinji)
[14]. Following the 2008 surveys, a trachoma elimination programme was devised and, as a
part of that programme, both districts received azithromycin MDA at yearly intervals for three
years (2011–2013).
Sampling strategy
For the purposes of the impact surveys, following WHO guidance, each district (Chikwawa
and Mchinji) was divided into three evaluation units (EUs) [3]. To estimate a prevalence of
TF, in children aged 1–9 years, of 10% in each EU, given a desired precision of ±3%, a 95%
confidence limit and a design effect of 2.65, 1,019 children should be examined [8]. The aver-
age Malawian household was estimated to contain 4 to 5 people, of who 1–2 are in the 1–9
years age range. Therefore, to achieve the required sample size, taking into account non-
response, 24 clusters (villages) were randomly selected in each EU and 30 households were
randomly selected, from a list of households, in each cluster. Every consenting member of
each selected household aged�1 year was examined.
Data collection
Data collection took place in June and July 2014. Prior to the onset of fieldwork, a workshop
was held for trachoma graders (ophthalmic clinical officers) and enumerators. Training
included quality control exercises of trachoma grading from slides in a classroom setting fol-
lowed by practical tests in the field [19].
Questionnaires were used to capture demographic information and data on household-
level access to water and sanitation. For the latter, questions were asked of the head of each
selected household, and (where relevant) sanitation facilities observed. All household mem-
bers, defined as those who slept in the household the night before, were eligible for trachoma
Pgp3 seroprevalence and trachoma in Malawi
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screening. Consenting individuals were examined for clinical signs of trachoma using a 2.5×
magnifying loupe and adequate sun- or torchlight. Trachoma grading was carried out accord-
ing to the WHO simplified grading system [20].
Ocular swabs and dried blood spots (DBS) were collected from children aged 1–9 years.
Ocular samples were collected using Dacron swabs (Puritan, Guilford, USA) passed across the
upper left tarsal conjunctiva, after everting the eyelid. Field control swabs were also taken,
once for every 50 swabs collected (with timing determined at random), by passing a clean
swab in the air within two inches of a child’s eyes. All swabs were placed in sterile tubes and
kept on cool packs in the field and frozen at -20˚C within 10 hours of collection. Blood samples
were collected by finger prick with a new, sterile lancet, and absorbed onto filter papers cali-
brated to absorb 10 μL of blood (TropBio, Townsville, Australia). These were then air-dried,
sealed in individual plastic bags and placed in larger bags with desiccant before being stored at
-20˚C.
Laboratory methods
Swabs were tested for C. trachomatis DNA using the GeneXpert CT/NG assay (Cepheid Inc.,
Sunnyvale, CA, USA). Swabs were rehydrated in 800 μL nuclease-free water and vortexed vig-
orously. Two hundred μL of suspension from each of five swabs was then combined to gener-
ate a pool [21]. Three hundred μL of the pool was added to 900 μL of CT/NG transport media
(Cepheid Inc.) and this total volume added to a GeneXpert CT/NG cartridge (Cepheid Inc.)
and tested according to the manufacturer’s instructions. In the case of a positive or invalid
result, all five samples making up the pool were then tested individually. Known positive and
negative controls, supplied by the London School of Hygiene & Tropical Medicine (London,
UK), were run every week during testing as a quality control measure.
Laboratory personnel were blind to the clinical status of subjects from whom samples were
taken and were unable to distinguish between ocular swabs and swabs included as field
controls.
DBS were tested, in duplicate, for antibodies against Pgp3 [22] according to the method
previously described [11, 22]. Serum was eluted overnight then applied to Immulon 2HB
microtiter plates (Southern Biotech, Birmingham, AL, USA) pre-sensitized with Pgp3 protein.
Bound antibody was detected with HRP-labelled mouse anti-human IgG (Fc)-HRP (Southern
Biotech). Plates were incubated, washed and 3,3’,5,5’-tetramethylbenzidine (KPL, Gaithers-
burg, MD, USA) was added before the reaction was stopped with 1N H2SO4. Absorbance was
read at 450 nm (A450) using a HaloLED 96 Microplate Reader (Dynamica, London, UK).
Readings were corrected for background by subtracting the average A450 of two blank wells
containing no serum. Values were normalised by dividing the mean of values for the two wells
against the mean for the two 200 U controls included on each plate [23].
Data entry and statistical analysis
All field data were collected using an Android smartphone app and uploaded to a password-
protected cloud-based server. Laboratory data were captured electronically on the GeneXpert
and HALO plate reader devices.
Data were analyzed using Stata version 14.2 (StataCorp LP, College Station, TX, USA).
Prevalence of TF, C. trachomatis infection and antibodies to Pgp3 were calculated and dis-
played with exact binomial confidence intervals. Correlations between EU-summarised preva-
lence of TF, C. trachomatis infection and antibodies to Pgp3 were plotted with lines of best-fit
and tested using Spearman’s rank correlation. Cluster-summarized prevalence of the three
Pgp3 seroprevalence and trachoma in Malawi
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indicators was mapped using ArcMap v10.3 (Environmental Systems Research Institute, Inc.
Redlands, CA, USA).
A finite mixture model was used to classify the samples as seropositive or seronegative
based on normalized A450 values [22]. The cutoff for seropositivity was defined as the mean of
the Gaussian distribution of the seronegative population plus three standard deviations of the
seronegative population [22].
Seroconversion rates (SCR) were calculated by fitting a simple reversible catalytic model to
the measured seroprevalence, stratified into yearly age-groups, using maximum likelihood
methods, assuming no seroreversion [24].
Case management
All individuals with TF were provided with two tubes of 1% tetracycline ointment and instruc-
tions for twice-daily use for six weeks. Cases of trichiasis were referred for surgery.
Ethics statement
The study adhered to the tenets of the Declaration of Helsinki and was approved by Malawi’s
Ministry of Health National Health Sciences Ethics and Research Committee. Written,
informed consent was obtained from the parent or guardian of all children. In the case of
adults whose eyes were examined but from whom no samples were taken, verbal consent was
obtained and documented electronically. CDC staff did not have contact with study partici-
pants and were determined to be non-engaged in the study.
Results
Overall, 13,556 individuals, representing 94.3% of the censused population, participated in the
study. Of these, 6,314 (43.9%) were children aged 1–9 years. Demographic characteristics of
individuals and households are given in Table 1.
The majority of households reported accessing their drinking water at boreholes (69%) and
70% of households were reportedly within 30 minutes of their water source (Table 1). Access
to sanitation was good, with over 90% of households reporting access to either shared or pri-
vate latrines (Table 1).
District-level prevalence of trichiasis in participants 15 years of age and older was 0.43% in
Chikwawa (13/2,999) and 0.12% (4/3,251) in Mchinji. There was no difference in the preva-
lence of TT amongst female (11/4,179; 0.26%) and male (6/2,071; 0.29%) participants.
Prevalence of TF amongst children aged 1–9 years ranged from 4.7% (95% CI 3.4–6.3) in
the EU of Kasisi/DHO to 7.2% (95% CI 5.8–8.9) in the EU of Makanda Gumba (Table 2).
Overall TF prevalence in children aged 1–9 years was 5.1% (95% CI 4.3–6.0) in Chikwawa dis-
trict and 6.4% (95% CI 5.6–7.3) in Mchinji (Table 2).
Ocular swabs were collected from 6,075 children. Of these, 185 ocular swabs gave invalid
results, indicating they did not contain detectable amounts of human DNA. Swabs from 24
children were missing. A positive or negative PCR result was obtained for the remaining 5,866
swabs (96.6% of the total). The prevalence of C. trachomatis infection was low, ranging from
0.1% (95% CI 0.0–0.6) in the EU of Ngabu Ngokwe to 0.7% in Makanda Gumba (95% CI 0.3–
1.3) (Table 2). District-level prevalence of infection was 0.2% (95% CI 0.1–0.4) in Chikwawa
and 0.4% (95% CI 0.2–0.7) in Mchinji (Table 2). Of the 264 negative field controls tested, none
gave a positive result for C. trachomatis DNA.
Pgp3 ELISA results were obtained for 97.4% of recruited children (5,917/6,075) aged 1–9
years. The mean absorbance value was 0.3581 (standard deviation 0.2765). Seroprevalence
was lowest in DHO Nkwazi [6.9% (95% CI 5.4–8.6)] and highest in Makanda Gumba [12.0%
Pgp3 seroprevalence and trachoma in Malawi
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(95% CI 10.1–14.0)] and increased with age. The lowest seroprevalence levels were found in
children aged 1 year [3.8%, (95% CI 2.4–5.6)] while the highest levels were in children aged
9 years [20.0%, (95% CI 16.8–23.4)] (Table 2). Seroprevalence was similar in both districts;
9.8% (95% CI 8.7–11.0) in Chikwawa and 9.5% (95% CI 8.5–10.6) in Mchinji (Table 2). The
Table 1. Characteristics of study participants.
Characteristic No. (%)
Total censused population 14,379
Gender
Male 6,097 (42.4)
Female 8,282 (57.6)
Age (years)
1–9 6,314 (43.9)
10–14 1,452 (10.1)
�15 6,613 (46.0)
Total population examined
Yes 13,556 (94.3)
No–absent 771 (5.4)
No–refused 48 (0.3)
No–other 4 (0.0)
Household characteristics
Main source of drinking water
Piped water into dwelling 62 (0.4)
Piped water into yard 165 (1.2)
Public tap 1,400 (9.7)
Borehole 9,920 (69.0)
Protected dug well 552 (3.8)
Unprotected dug well 1,698 (11.8)
Unprotected spring 175 (1.2)
Surface water 382 (2.7)
Other 25 (0.2)
Habitual time to fetch water
Water source in yard 420 (2.9)
Less than 30 minutes 10,081 (70.1)
30 minutes to 1 hour 3,232 (22.5)
More than 1 hour 646 (4.5)
Access to latrine
Shared or public latrine 3,513 (24.4)
Private latrine 9,686 (67.4)
No structure, outside house 106 (0.7)
No structure, in bush 1,066 (7.4)
Other 8 (0.1)
Type of latrine (observed)
Flush/pour 86 (0.5)
Ventilated, improved pit latrine 33 (0.2)
Pit latrine 13,221 (91.9)
No facilities, bush or field 1,036 (7.2)
Other 23 (0.2)
https://doi.org/10.1371/journal.pntd.0007749.t001
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seroconversion rate (SCR) was 0.0283 (95% CI: 0.0275–0.029) per year for Chikwawa and
0.021 (95% CI: 0.020–0.021) for Mchinji.
Geographical distributions of TF, C. trachomatis infection and prevalence of anti-Pgp3 anti-
bodies in children aged 1–9 years are shown in Fig 1. The highest prevalence of all three indica-
tors were found in the EU of Makanda Gumba (Table 2).
No association was seen between any of EU-summarised prevalence of TF and C. trachoma-
tis infection (Fig 2A), EU-summarised prevalence of TF and anti-Pgp3 antibodies and EU-
summarised prevalence of C. trachomatis infection and anti-Pgp3 antibodies (Fig 2C).
Discussion
Our data show that prevalence of TF one year following the completion of three annual rounds
of MDA was low in all six EUs surveyed. Two EUs have reached the elimination TF prevalence
threshold of less than 5% in children aged 1–9 years [25] while the remaining four EUs are
nearing this target. The prevalence of ocular C. trachomatis infection in the same children was
0.3%, considerably lower than that of active disease. The persistence of low-level rates of TF in
communities where ocular infection is rare has previously been clearly documented in tra-
choma-endemic populations approaching elimination [4] and has been responsible, in part,
Table 2. Prevalence of trachomatous inflammation—follicular (TF), C. trachomatis infection and anti-Pgp3 antibodies in participants aged 1–9 years.
TF Ocular Ct infection Anti-Pgp3 antibodies
N n % 95% CI1 N n % 95% CI1 N N % 95% CI1
Overall 6,075 354 5.8 5.3–6.4 5,866 18 0.3 0.2–0.5 5,917 570 9.6 8.9–10.4
EU
Chapananga2 937 46 4.9 3.6–6.5 924 2 0.2 0.0–0.8 916 104 11.4 9.4–13.6
Ngabu Ngokwe2 914 52 5.7 4.3–7.4 881 1 0.1 0.0–0.6 897 88 9.8 7.9–11.9
Kasisi/DHO2 869 41 4.7 3.4–6.3 863 2 0.2 0.0–0.8 830 67 8.1 6.3–10.1
Makanda Gumba3 1,120 81 7.2 5.8–8.9 1,085 7 0.7 0.3–1.3 1,117 134 12.0 10.1–14.0
Luzi Kochilira3 1,183 77 6.5 5.2–8.1 1,119 3 0.3 0.1–0.8 1,139 107 9.4 7.8–11.2
DHO Nkwazi3 1,052 57 5.4 4.1–7.0 994 3 0.3 0.1–0.9 1,018 70 6.9 5.4–8.6
District
Chikwawa 2,720 139 5.1 4.3–6.0 2,668 5 0.2 0.1–0.4 2,643 259 9.8 8.7–11.0
Mchinji 3,355 215 6.4 5.6–7.3 3,198 13 0.4 0.2–0.7 3,274 311 9.5 8.5–10.6
Gender
Female 3,151 192 6.1 5.3–7.0 3,033 12 0.4 0.2–0.7 3,076 293 9.5 8.5–10.6
Male 2,924 162 5.5 4.7–6.4 2,833 6 0.2 0.1–0.5 2,841 277 9.8 8.7–10.9
Age (years)
1 650 37 5.7 4.0–7.8 626 2 0.3 0.0–1.1 637 24 3.8 2.4–5.6
2 910 85 9.3 7.5–11.4 852 2 0.2 0.0–0.8 882 39 4.4 3.2–6.0
3 800 55 6.9 5.2–8.9 765 2 0.3 0.0–0.9 780 56 7.2 5.5–9.2
4 738 53 7.2 5.4–9.3 710 1 0.1 0.0–0.8 716 48 6.7 5.0–8.8
5 724 39 5.4 3.9–7.3 703 2 0.3 0.0–1.0 708 64 9.0 7.0–11.4
6 603 43 7.1 5.2–9.5 589 2 0.3 0.0–1.2 591 73 12.4 9.8–15.3
7 596 20 3.4 2.0–5.1 585 4 0.7 0.2–1.7 581 76 13.1 10.4–16.1
8 453 13 2.9 1.5–4.9 442 2 0.5 0.1–1.6 436 73 16.7 13.4–20.6
9 601 9 1.5 0.7–2.8 594 1 0.2 0.0–0.9 586 117 20.0 16.8–23.4
1Exact binomial confidence interval
2EU in Chikwawa
3EU in Mchinji
https://doi.org/10.1371/journal.pntd.0007749.t002
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Fig 1. Mapping of indicators of trachoma in Chikwawa and Mchinji. Cluster level prevalence of (A) TF, (B) C.
trachomatis infection and (C) anti-Pgp3 antibodies.
https://doi.org/10.1371/journal.pntd.0007749.g001
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Fig 2. Correlations between EU-summarised prevalence of TF, C. trachomatis infection and anti-Pgp3 antibodies.
(A) Correlation of EU-summarised prevalence of TF and C. trachomatis infection. (B) Correlation of EU-summarised
prevalence of TF and anti-Pgp3 antibodies. (C) Correlation of EU-summarised prevalence of C. trachomatis infection
and anti-Pgp3 antibodies. EUs are represented by green dots. Lines of best fit are shown in blue. Shaded areas denote
95% confidence intervals.
https://doi.org/10.1371/journal.pntd.0007749.g002
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for prompting the discussion of whether TF is the most appropriate marker on which to base
decisions to stop MDA.
According to current guidelines, antibiotic MDA should be stopped only when impact sur-
veys in EUs (population 100,000–250,000 people) indicate the prevalence of TF in children
aged 1–9 years is below 5% [25]. The present results therefore indicate that another year of
antibiotic MDA is warranted in four of the six EUs before re-survey. Yet, when viewed along-
side PCR data that indicate a virtual absence of C. trachomatis infection [prevalence 0.3% (95%
CI 0.2–0.5)], doubt is cast on the need for further antibiotic use. There is, however, no current
recommendation for programmatic application of data on infection and PCR testing remains
expensive. Serology, which can be conducted at much lower cost and multiplexed for inte-
grated surveillance of multiple infectious diseases [10], may prove a viable alternate indicator
for stopping MDA and undertaking post-MDA surveillance.
Overall seroprevalence in the current study (9.6%) was somewhat higher than prevalence of
TF (5.8%), which is consistent with the notion that anti-Pgp3 antibody responses are markers
of cumulative exposure rather than of persistent infection [26–27]. Furthermore, there was an
increase in seropositivity with age seen in the current study, which also reflects cumulative
exposure.
The cut-off for determining seropositivity with the ELISA assay used in this study was cal-
culated using the finite mixture model, following the approach recommended by Migchelsen
et al. [22]. This approach may over-estimate prevalence relative to other methods, such as the
receiver operating characteristic (ROC) curves [22–23] used elsewhere [28–30]. Comparison
to other studies is further complicated by the varying means of detecting Pgp3 antibodies.
Many studies have used bead-based immunoassays [12, 26–27, 30–31], which are more expen-
sive and technically challenging than the ELISA-based method employed here. However, a
direct comparison of the two assays (EISA versus bead-based immunoassay) in a pre-valida-
tion survey in Ghana showed similar population-level prevalence [5.5% (95% CI: 4.8–6.3) for
ELISA; 4.3% (95% CI: 3.7–4.9) for bead-based assay] [32] with calculated SCRs being virtually
identical [0.013 (95% CI: 0.011–0.016) for ELISA; 0.012 (95% CI: 0.009–0.016) for bead-based
assay). While further direct comparisons of platforms in large-scale surveys are needed, initial
studies suggest good agreement of data from different assay platforms, especially if the SCR is
the output of greatest interest.
Before serology could be adopted as an alternative or adjunct to TF prevalence for stopping
MDA and post-MDA decision-making, seropositivity thresholds would need to be established.
One approach might be to focus on the youngest children–those born during MDA or after
its cessation and presumably very infrequently exposed to ocular C. trachomatis infection.
Because the current survey was conducted in the year following completion of the third round
of MDA and because children under 1 year of age, who might have had transplacentally-trans-
ferred maternal antibodies, were not eligible for inclusion, we do not have data from children
born after the cessation of MDA. The youngest children in this study (aged 1–3 years) were
born during the three-year MDA campaign and had similar seroprevalence to 1–3-year-olds
in elimination settings; in post-validation settings, 1–3-year-olds are reported to have a
prevalence of anti-Pgp3 antibodies of<6%, as measured primarily by bead-based assays [12,
32–34].
A second approach would be to look at overall seroprevalence in 1–9-year-olds. While the
prevalence of anti-Pgp3 antibodies here was much lower than that in populations that have
high transmission rates [27–28], the antibody prevalence was higher than in communities
where longitudinal follow-up and tests for infection have documented sustained elimination
of ocular C. trachomatis infection [12, 29–30]. For example, a study conducted 10 years after
cessation of antibiotic MDA in Rombo district of Tanzania found just 3.5% (95% CI: 1.4–7.1)
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of 1–9-year-olds to have anti-Pgp3 antibodies [12], less than the 9.6% seropositivity (95% CI:
8.9–10.4) seen in the children in the current study. In The Gambia, 4.2% (95% CI: 2.9–5.9) of
children aged 1–9 years were positive for Pgp3 antibodies 5 years after MDA [29], while in
Nepal 3.4% (95% CI: 1.4–6.9) of children aged 9 years were seropositive 4 years following ces-
sation of MDA [30].
A third approach would be to look at trends in antibody responses with age. The SCR esti-
mated for the two districts here [0.0283 (95% CI: 0.0275–0.029) per year for Chikwawa and
0.021 (95% CI: 0.020–0.021) for Mchinji] were higher than that predicted to be associated
with<5% TF [SCR of 0.015 (95% CI: 0.0–049)] [35], but the confidence intervals were over-
lapping. An algorithm combining these two metrics–seroprevalence and SCR–may have utility
as well, particularly in settings like the Malawi districts studied here, where SCR estimates are
close to but not below predictions for TF<5%. While it is unclear that this level of seropositiv-
ity is definitively associated with local elimination, the current data add to the evidence base
that will be needed to determine appropriate thresholds for potential use of serology for
surveillance.
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